Asset Details
Do you wish to reserve the book?
Prognostic value of the platelet-to-lymphocyte ratio in colorectal cancer patients undergoing chemotherapy: a systematic review and meta-analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Prognostic value of the platelet-to-lymphocyte ratio in colorectal cancer patients undergoing chemotherapy: a systematic review and meta-analysis
Do you wish to request the book?
Prognostic value of the platelet-to-lymphocyte ratio in colorectal cancer patients undergoing chemotherapy: a systematic review and meta-analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Prognostic value of the platelet-to-lymphocyte ratio in colorectal cancer patients undergoing chemotherapy: a systematic review and meta-analysis
2025
Overview
Background
This research aimed to estimate the prognostic value of the platelet-to-lymphocyte ratio (PLR) in colorectal cancer (CRC) patients receiving chemotherapy.
Methods
Embase, the Cochrane Library, Web of Science, and PubMed were searched from inception to March 20, 2025. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to appraise the predictive significance of PLR among CRC patients receiving chemotherapy. The robustness of the findings and potential publication bias were assessed by sensitivity analysis and Egger’s test, respectively. The impact of confounding variables was investigated through subgroup and regression analyses.
Results
In total, 33 studies involving 7,529 individuals were included. Statistical analysis of categorical variables demonstrated that an increased PLR was significantly related to overall survival (OS) (HR = 1.33, 95% CI = 1.14–1.54), progression-free survival (PFS) (HR = 1.32, 95% CI = 1.06–1.63), and relapse-free survival (RFS) (HR = 1.77, 95% CI = 1.13–2.77) in CRC patients receiving chemotherapy, whereas no significant relationship was found with disease-free survival (DFS) (HR = 1.19, 95% CI = 0.84–1.69). Subgroup analyses indicated that, among metastatic CRC patients, a higher PLR was significantly linked to unfavorable OS and DFS. In CRC patients receiving adjuvant chemotherapy or chemotherapy with or without targeted therapy, high PLR was significantly related to worse OS and PFS.
Conclusion
An elevated PLR is related to adverse prognosis among CRC patients undergoing chemotherapy. In clinical practice, PLR may be a promising and cost-effective predictive marker for this population.
Publisher
BioMed Central,BioMed Central Ltd,BMC
